Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2005-09-29 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2005
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the initiation of a Phase 1a clinical trial for a drug candidate, XTL-6865, for hepatitis C treatment. The document is dated September 2005 and includes company contact information and a cautionary statement about forward-looking statements. There are no financial statements or detailed financial analysis present. The document is an announcement of a corporate milestone and clinical trial initiation rather than a financial report or regulatory certification. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2005-09-29 English
Immediate report on other matter
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of a Phase 1a clinical trial for a drug candidate (XTL-6865) by XTL Biopharmaceuticals Ltd. It includes details about the trial, regulatory filings (IND with FDA), and company background. There are no financial statements, no detailed financial performance data, no voting results, no management or board changes, no earnings data, and no regulatory certifications. The document is short (3305 characters) and serves as a corporate announcement about a clinical trial milestone rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial compliance. It is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2005-09-29 Hebrew (modern)
Immediate report on other matter
Report Publication Announcement Classification · 98% confidence The document is very short (1687 characters) and contains a header indicating it is an "Immediate report on other matter." Crucially, it states, "Attached file *21-05_XTL6865_Clinical_Trial_29Sep05_isa.pdf*" and does not contain the full content of a financial report, audit, or presentation. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces that another report is attached or published, it should be classified as a Report Publication Announcement (RPA). Since this is an immediate report about a clinical trial initiation, it is an announcement of material information, fitting the RPA category better than the general fallback (RNS), as RPA specifically covers announcements about the publication of company reports/updates.
2005-09-29 English
Immediate report on other matter
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a License and Asset Purchase Agreement between XTLbio and VivoQuest Inc. It details the transaction terms, the addition of VivoQuest's R&D team to XTLbio, and the strategic benefits of the acquisition. It also announces a conference call to discuss the transaction and provides contact information. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is primarily an announcement of a capital transaction and related business update, not a full financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a call transcript but mentions a conference call. The best fitting category is Capital/Financing Update (CAP), as it relates to a financing and licensing transaction and business development update.
2005-09-21 Hebrew (modern)
Immediate report on other matter
Report Publication Announcement Classification · 98% confidence The document is extremely short (1650 chars) and contains a clear instruction: "*please see attached*" followed by a reference to an attached file named '20-05_VivoQuest_Closing_press_release_21Sep05_isa.pdf'. This structure indicates that the document itself is merely an announcement or cover sheet for a more substantial report or press release, rather than the full report content. The presence of the date 21/09/2005 and the reference to a press release strongly suggests an announcement of a material event. Given the 'MENU VS MEAL' rule, this is classified as a Report Publication Announcement (RPA) because it announces the release of another document (a press release/report) rather than containing the full substance of a specific filing type like ER or LTR. If it were the actual press release, it would likely be classified as ER or LTR, but here it functions as a notification of publication.
2005-09-21 English
Interim / Quarterly Report 2005
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd., reporting interim financial results for the six months ended June 30, 2005. It includes detailed financial data such as balance sheets, statements of operations, and management commentary on business strategy and financial performance. The document is not merely an announcement or a certification but contains substantive financial statements and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2005-09-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.